Evidence map›Paper›PMID 42741717›Full record

SynthesisInternational journal of chronic obstructive pulmonary disease2026

Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review.

Christopher E Brightling, Klaus F Rabe, Dave Singh, MeiLan K Han, Mohit Bhutani, Jean Bourbeau, Parameswaran Nair, M Bradley Drummond, Elizabeth A Gandhi, Navreet S Sindhwani and 3 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christopher E BrightlingInstitute for Lung Health, National Institute for Health and Care Research Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Klaus F RabeDepartment of Pneumology, LungenClinic Grosshansdorf, Grosshansdorf, Germany.ORCID 0000-0002-7020-1401
Dave SinghManchester University NHS Foundation Trust, University of Manchester, Manchester, UK.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Mohit BhutaniDivision of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Jean BourbeauMcGill University Health Centre, McGill University, Montreal, QC, Canada.
Parameswaran NairFirestone Institute for Respiratory Health, St Joseph's Healthcare & McMaster University, Hamilton, ON, Canada.
M Bradley DrummondDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-6968-4610
Elizabeth A GandhiPharmaGenesis Cambridge, Cambridge, UK.ORCID 0000-0001-5512-915X
Navreet S SindhwaniLate-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.
Nestor A MolfinoGlobal Development, Inflammation, R&D, Amgen, Thousand Oaks, CA, USA.
Amit D ParulekarRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Sandhia S PonnarambilLate-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing number of biologics are approved or in development for the treatment of chronic obstructive pulmonary disease (COPD). Many reduce acute exacerbations of COPD (AECOPD), particularly among patients with an elevated blood eosinophil count (BEC). In this systematic review, PubMed and Ovid (MEDLINE and Embase) were searched for phase 2 and 3 randomized controlled trials of biologics in patients with moderate to very severe COPD published between database inception and July 9, 2025. AECOPD rates and changes from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV

Indexed as

Biological ProductsLungPulmonary Disease, Chronic ObstructiveAgedDisease ProgressionEosinophilsFemaleForced Expiratory VolumeHumansMaleRecovery of FunctionSeverity of Illness IndexTreatment OutcomeBiological ProductsbiologicsCOPDeosinophilsexacerbationshealth-related quality of lifelung function

Identifiers

PMID42741717
PMCPMC13573804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.